REPL - Replimune surges as Cantor upgrades on possible FDA U-turn on lead drug
2025-07-30 14:43:59 ET
More on Replimune Group
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
- Replimune Group: Analysts Are More Optimistic Than The Market
- Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs
- Replimune rebounds despite analyst downgrades on FDA rejection